Optimizing Care for Lower-Risk Myelodysplastic Syndromes: Translating Evidence to Clinical Practice - Episode 4

Tailoring Treatment for LR-MDS: Patient Factors, Treatment Goals, and Patient Outcomes

October 7, 2024

James K. McCloskey, MD, John Theurer Cancer Center, Thomas W. LeBlanc, MD, MA

Panelists discuss how treatment goals for patients with lower-risk MDS are established and analyze the findings of Oliva et al’s study on the relationship between hemoglobin levels and quality of life in transfusion-dependent patients with lower-risk MDS treated with luspatercept or epoetin.

EP. 1: Understanding Myelodysplastic Syndromes (MDS): Diagnosis, Classification, and Risk Assessment

EP. 2: Navigating the Heterogeneity of LR-MDS: Importance of Molecular Testing & Risk Stratifying

EP. 3: Clinical Scenario 1: 76-Year-Old Man With Newly Diagnosed MDS With Symptomatic Anemia, RS Positive

Now Viewing

EP. 4: Tailoring Treatment for LR-MDS: Patient Factors, Treatment Goals, and Patient Outcomes

EP. 5: First-Line Luspatercept in LR-MDS: A Deep Dive Into the COMMANDS Trial and Clinical Implications in the Real-Life Practice Setting

EP. 6: Managing Luspatercept Therapy: Dosing, Adverse Effects, and Monitoring

EP. 7: Second-Line LR- MDS Setting: Treatment Options and Considerations

EP. 8: Patient Profile: 66-Year-Old Woman with Newly Diagnosed LR-MDS, RS Negative

EP. 9: Luspatercept Role in the RS-Negative Population and Expert Perspectives on the Role of EPO Levels

EP. 10: First-Line ESA vs Luspatercept in LR-MDS: Choosing the Most Appropriate Treatment Option for Each Individual Patient

EP. 11: Imetelstat and IMerge Trial Review

EP. 12: Looking Ahead in LR-MDS: Future Agents and/or Combination Strategies

EP. 13: The Future of Lower-Risk MDS: Closing Thoughts and Unmet Needs

Video content above is prompted by the following:

What are your treatment goals for patients with lower-risk MDS?
Please comment on the findings of Oliva et al with regard to the relationship between hemoglobin levels and quality of life in transfusion-dependent patients with lower-risk MDS treated with luspatercept or epoetin (EHA 2024; abstract P774).